{"product_id":"ostarine-50x10mg","title":"MK2886(Ostarine) 100x10mg","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                             \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp data-start=\"225\" data-end=\"764\"\u003e\u003cstrong\u003eMK2886(Ostarine)\u003c\/strong\u003e is an oral, non-steroidal \u003cstrong data-start=\"294\" data-end=\"342\"\u003eselective androgen receptor modulator (SARM)\u003c\/strong\u003e designed to deliver \u003cstrong data-start=\"363\" data-end=\"411\"\u003eanabolic effects in skeletal muscle and bone\u003c\/strong\u003e with comparatively \u003cstrong data-start=\"431\" data-end=\"468\"\u003eless stimulation of prostate\/skin\u003c\/strong\u003e than testosterone. It binds the \u003cstrong data-start=\"501\" data-end=\"527\"\u003eandrogen receptor (AR)\u003c\/strong\u003e, drives \u003cstrong data-start=\"536\" data-end=\"553\"\u003eARE-regulated\u003c\/strong\u003e transcription, does \u003cstrong data-start=\"574\" data-end=\"581\"\u003enot\u003c\/strong\u003e aromatize or undergo 5-α reduction, and shows \u003cstrong data-start=\"628\" data-end=\"673\"\u003etissue-selective co-activator recruitment\u003c\/strong\u003e. Enobosarm is \u003cstrong data-start=\"688\" data-end=\"712\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e and is \u003cstrong data-start=\"720\" data-end=\"742\"\u003eprohibited by WADA\u003c\/strong\u003e as an anabolic agent.\u003c\/p\u003e\n\u003chr data-start=\"766\" data-end=\"769\"\u003e\n\u003ch3 data-start=\"771\" data-end=\"831\"\u003eAdditional Benefits of Enobosarm Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"833\" data-end=\"3099\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"833\" data-end=\"861\"\u003e\n\u003ctr data-start=\"833\" data-end=\"861\"\u003e\n\u003cth data-start=\"833\" data-end=\"843\" data-col-size=\"sm\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"843\" data-end=\"861\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"872\" data-end=\"3099\"\u003e\n\u003ctr data-start=\"872\" data-end=\"1204\"\u003e\n\u003ctd data-start=\"872\" data-end=\"919\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"874\" data-end=\"918\"\u003e1 Lean-mass and function (human signals)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"919\" data-end=\"1204\" data-col-size=\"xl\"\u003ePhase 2 studies in older\/postmenopausal adults showed \u003cstrong data-start=\"975\" data-end=\"1037\"\u003edose-dependent fat-free-mass gains (~1–1.5 kg over 12 wks)\u003c\/strong\u003e and \u003cstrong data-start=\"1042\" data-end=\"1085\"\u003eimproved stair-climb power\/leg strength\u003c\/strong\u003e vs placebo. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Clinical Endocrinology \u0026amp; Metabolism; Journal of Cachexia, Sarcopenia and Muscle\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1205\" data-end=\"1492\"\u003e\n\u003ctd data-start=\"1205\" data-end=\"1239\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1207\" data-end=\"1238\"\u003e2 Anti-catabolic protection\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1239\" data-end=\"1492\" data-col-size=\"xl\"\u003eIn disuse\/illness models, enobosarm \u003cstrong data-start=\"1277\" data-end=\"1303\"\u003epreserves myofiber CSA\u003c\/strong\u003e and lowers \u003cstrong data-start=\"1315\" data-end=\"1330\"\u003eMAFbx\/MuRF1\u003c\/strong\u003e expression, attenuating muscle loss during immobilization or glucocorticoid exposure. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;FASEB Journal; American Journal of Physiology–Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1493\" data-end=\"1745\"\u003e\n\u003ctd data-start=\"1493\" data-end=\"1523\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1495\" data-end=\"1522\"\u003e3 Bone-anabolic signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1523\" data-end=\"1745\" data-col-size=\"xl\"\u003eRodent osteopenia studies show \u003cstrong data-start=\"1556\" data-end=\"1565\"\u003e↑ BMD\u003c\/strong\u003e, improved \u003cstrong data-start=\"1576\" data-end=\"1608\"\u003etrabecular microarchitecture\u003c\/strong\u003e, and stronger \u003cstrong data-start=\"1623\" data-end=\"1643\"\u003ethree-point bend\u003c\/strong\u003e metrics with limited prostate stimulation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Bone and Mineral Research; Bone\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1746\" data-end=\"2024\"\u003e\n\u003ctd data-start=\"1746\" data-end=\"1787\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"1748\" data-end=\"1786\"\u003e4 Cancer cachexia (mixed outcomes)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1787\" data-end=\"2024\" data-col-size=\"xl\"\u003ePhase 2 trials reported \u003cstrong data-start=\"1813\" data-end=\"1845\"\u003eFFM and performance benefits\u003c\/strong\u003e in NSCLC\/other cancers; \u003cstrong data-start=\"1870\" data-end=\"1889\"\u003ePhase 3 (POWER)\u003c\/strong\u003emissed primary endpoints overall but suggested \u003cstrong data-start=\"1937\" data-end=\"1961\"\u003eresponsive subgroups\u003c\/strong\u003e—ongoing phenotyping work. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;JCSM; The Oncologist\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2025\" data-end=\"2278\"\u003e\n\u003ctd data-start=\"2025\" data-end=\"2069\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2027\" data-end=\"2068\"\u003e5 AR-positive ER⁺\/HER2⁻ breast cancer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2069\" data-end=\"2278\" data-col-size=\"xl\"\u003eAs a \u003cstrong data-start=\"2076\" data-end=\"2100\"\u003eselective AR agonist\u003c\/strong\u003e, enobosarm shows \u003cstrong data-start=\"2118\" data-end=\"2140\"\u003eantitumor activity\u003c\/strong\u003e in AR-enriched ER⁺ disease and is being explored \u003cstrong data-start=\"2190\" data-end=\"2225\"\u003ealone or with CDK4\/6 inhibitors\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Cancer Research; Annals of Oncology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2279\" data-end=\"2517\"\u003e\n\u003ctd data-start=\"2279\" data-end=\"2323\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2281\" data-end=\"2322\"\u003e6 Sarcopenic obesity \u0026amp; rehabilitation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2323\" data-end=\"2517\" data-col-size=\"xl\"\u003eOral dosing \u003cstrong data-start=\"2337\" data-end=\"2374\"\u003eadds to resistance-training gains\u003c\/strong\u003e and may speed \u003cstrong data-start=\"2389\" data-end=\"2413\"\u003epost-hospitalization\u003c\/strong\u003e recovery—needs definitive RCTs. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Geriatrics \u0026amp; Gerontology International; Sports Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2518\" data-end=\"2735\"\u003e\n\u003ctd data-start=\"2518\" data-end=\"2553\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2520\" data-end=\"2552\"\u003e7 Physical performance \u0026amp; QoL\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2553\" data-end=\"2735\" data-col-size=\"xl\"\u003eImprovements in \u003cstrong data-start=\"2571\" data-end=\"2610\"\u003estair power, chair-rise, gait speed\u003c\/strong\u003e and \u003cstrong data-start=\"2615\" data-end=\"2644\"\u003epatient-reported outcomes\u003c\/strong\u003e parallel anabolic changes in small studies. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;MSSE; Quality of Life Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2736\" data-end=\"2929\"\u003e\n\u003ctd data-start=\"2736\" data-end=\"2768\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2738\" data-end=\"2767\"\u003e8 Erythropoiesis (modest)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2768\" data-end=\"2929\" data-col-size=\"xl\"\u003eAR engagement can \u003cstrong data-start=\"2788\" data-end=\"2828\"\u003eslightly raise hemoglobin\/hematocrit\u003c\/strong\u003e, typically less than testosterone—monitor in at-risk patients. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hematology; Andrology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2930\" data-end=\"3099\"\u003e\n\u003ctd data-start=\"2930\" data-end=\"2955\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"2932\" data-end=\"2954\"\u003e9 Oral convenience\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2955\" data-end=\"3099\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2957\" data-end=\"2976\"\u003eOnce-daily oral\u003c\/strong\u003e dosing and ~24-h half-life support adherence relative to injectables. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Pharmacology \u0026amp; Therapeutics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3101\" data-end=\"3104\"\u003e\n\u003ch2 data-start=\"3106\" data-end=\"3141\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"3143\" data-end=\"3178\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"3179\" data-end=\"3453\"\u003eEnobosarm binds \u003cstrong data-start=\"3195\" data-end=\"3201\"\u003eAR\u003c\/strong\u003e → nuclear translocation → \u003cstrong data-start=\"3228\" data-end=\"3235\"\u003eARE\u003c\/strong\u003e activation. In muscle, it up-regulates \u003cstrong data-start=\"3275\" data-end=\"3294\"\u003emTOR\/S6K\/4E-BP1\u003c\/strong\u003e and local \u003cstrong data-start=\"3305\" data-end=\"3314\"\u003eIGF-1\u003c\/strong\u003e, and \u003cstrong data-start=\"3320\" data-end=\"3345\"\u003edown-shifts atrogenes\u003c\/strong\u003e; in bone, it promotes \u003cstrong data-start=\"3368\" data-end=\"3390\"\u003eosteoblastogenesis\u003c\/strong\u003e (Wnt\/β-catenin\/Osterix) and may secondarily reduce resorption.\u003c\/p\u003e\n\u003ch3 data-start=\"3455\" data-end=\"3482\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3484\" data-end=\"3835\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3484\" data-end=\"3526\"\u003e\n\u003ctr data-start=\"3484\" data-end=\"3526\"\u003e\n\u003cth data-start=\"3484\" data-end=\"3494\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3494\" data-end=\"3515\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3515\" data-end=\"3526\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3541\" data-end=\"3835\"\u003e\n\u003ctr data-start=\"3541\" data-end=\"3620\"\u003e\n\u003ctd data-start=\"3541\" data-end=\"3557\" data-col-size=\"sm\"\u003eAR → mTOR\/S6K\u003c\/td\u003e\n\u003ctd data-start=\"3557\" data-end=\"3601\" data-col-size=\"md\"\u003e↑ protein synthesis, myofiber hypertrophy\u003c\/td\u003e\n\u003ctd data-start=\"3601\" data-end=\"3620\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3621\" data-end=\"3689\"\u003e\n\u003ctd data-start=\"3621\" data-end=\"3650\" data-col-size=\"sm\"\u003eAR → Wnt\/β-catenin\/Osterix\u003c\/td\u003e\n\u003ctd data-start=\"3650\" data-end=\"3681\" data-col-size=\"md\"\u003e↑ osteoblast activity, ↑ BMD\u003c\/td\u003e\n\u003ctd data-start=\"3681\" data-end=\"3689\" data-col-size=\"sm\"\u003eBone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3690\" data-end=\"3767\"\u003e\n\u003ctd data-start=\"3690\" data-end=\"3717\" data-col-size=\"sm\"\u003e↓ FoxO\/ubiquitin ligases\u003c\/td\u003e\n\u003ctd data-start=\"3717\" data-end=\"3747\" data-col-size=\"md\"\u003e↓ proteolysis (MAFbx\/MuRF1)\u003c\/td\u003e\n\u003ctd data-start=\"3747\" data-end=\"3767\" data-col-size=\"sm\"\u003eCatabolic stress\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3768\" data-end=\"3835\"\u003e\n\u003ctd data-start=\"3768\" data-end=\"3799\" data-col-size=\"sm\"\u003eMyostatin\/activin cross-talk\u003c\/td\u003e\n\u003ctd data-start=\"3799\" data-end=\"3825\" data-col-size=\"md\"\u003eShifts toward anabolism\u003c\/td\u003e\n\u003ctd data-start=\"3825\" data-end=\"3835\" data-col-size=\"sm\"\u003eMuscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3837\" data-end=\"3840\"\u003e\n\u003ch2 data-start=\"3842\" data-end=\"3864\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3866\" data-end=\"4254\"\u003e\n\u003cli data-start=\"3866\" data-end=\"3898\"\u003e\n\u003cp data-start=\"3868\" data-end=\"3898\"\u003e\u003cstrong data-start=\"3868\" data-end=\"3878\"\u003eRoute:\u003c\/strong\u003e Oral, once daily.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3899\" data-end=\"3953\"\u003e\n\u003cp data-start=\"3901\" data-end=\"3953\"\u003e\u003cstrong data-start=\"3901\" data-end=\"3915\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-start=\"3916\" data-end=\"3925\"\u003e~24 h\u003c\/strong\u003e (steady state ~5–7 days).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3954\" data-end=\"4021\"\u003e\n\u003cp data-start=\"3956\" data-end=\"4021\"\u003e\u003cstrong data-start=\"3956\" data-end=\"3971\"\u003eAbsorption:\u003c\/strong\u003e Good oral bioavailability; minimal food effect.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4022\" data-end=\"4103\"\u003e\n\u003cp data-start=\"4024\" data-end=\"4103\"\u003e\u003cstrong data-start=\"4024\" data-end=\"4039\"\u003eMetabolism:\u003c\/strong\u003e Hepatic oxidative\/conjugative pathways; high protein binding.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4104\" data-end=\"4164\"\u003e\n\u003cp data-start=\"4106\" data-end=\"4164\"\u003e\u003cstrong data-start=\"4106\" data-end=\"4122\"\u003eElimination:\u003c\/strong\u003e Renal\/hepatic excretion of metabolites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4165\" data-end=\"4254\"\u003e\n\u003cp data-start=\"4167\" data-end=\"4254\"\u003e\u003cstrong data-start=\"4167\" data-end=\"4178\"\u003eDoping:\u003c\/strong\u003e \u003cstrong data-start=\"4179\" data-end=\"4204\"\u003eLong-term metabolites\u003c\/strong\u003e enable detection \u003cstrong data-start=\"4222\" data-end=\"4231\"\u003eweeks\u003c\/strong\u003e after discontinuation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4256\" data-end=\"4259\"\u003e\n\u003ch2 data-start=\"4261\" data-end=\"4306\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4308\" data-end=\"4338\"\u003e4.1 Healthy\/Older Adults\u003c\/h3\u003e\n\u003cp data-start=\"4339\" data-end=\"4511\"\u003ePhase 2 trials: \u003cstrong data-start=\"4355\" data-end=\"4378\"\u003elean-mass increases\u003c\/strong\u003e with favorable trends in \u003cstrong data-start=\"4404\" data-end=\"4422\"\u003estrength\/power\u003c\/strong\u003e and \u003cstrong data-start=\"4427\" data-end=\"4448\"\u003ephysical function\u003c\/strong\u003e; \u003cstrong data-start=\"4450\" data-end=\"4480\"\u003ereversible HPG suppression\u003c\/strong\u003e and \u003cstrong data-start=\"4485\" data-end=\"4501\"\u003eHDL lowering\u003c\/strong\u003e observed.\u003c\/p\u003e\n\u003ch3 data-start=\"4513\" data-end=\"4531\"\u003e4.2 Oncology\u003c\/h3\u003e\n\u003cp data-start=\"4532\" data-end=\"4798\"\u003e\u003cstrong data-start=\"4532\" data-end=\"4545\"\u003eCachexia:\u003c\/strong\u003e Mixed—benefits in body composition\/performance in Phase 2, \u003cstrong data-start=\"4605\" data-end=\"4633\"\u003ePhase 3 overall negative\u003c\/strong\u003e on primary function endpoints.\u003cbr data-start=\"4664\" data-end=\"4667\"\u003e\u003cstrong data-start=\"4667\" data-end=\"4685\"\u003eBreast cancer:\u003c\/strong\u003e AR-positive ER⁺ cohorts show \u003cstrong data-start=\"4715\" data-end=\"4736\"\u003eclinical activity\u003c\/strong\u003e signals; combinations with \u003cstrong data-start=\"4764\" data-end=\"4785\"\u003eCDK4\/6 inhibitors\u003c\/strong\u003e under study.\u003c\/p\u003e\n\u003ch3 data-start=\"4800\" data-end=\"4827\"\u003e4.3 Orthopedics\/Rehab\u003c\/h3\u003e\n\u003cp data-start=\"4828\" data-end=\"4976\"\u003eEarly translational efforts pair enobosarm with \u003cstrong data-start=\"4876\" data-end=\"4911\"\u003eprogressive resistance training\u003c\/strong\u003e to shorten \u003cstrong data-start=\"4923\" data-end=\"4943\"\u003etime-to-function\u003c\/strong\u003e after immobilization or surgery.\u003c\/p\u003e\n\u003cblockquote data-start=\"4978\" data-end=\"5180\"\u003e\n\u003cp data-start=\"4980\" data-end=\"5180\"\u003e\u003cstrong data-start=\"4980\" data-end=\"5006\"\u003eEvidence quality note:\u003c\/strong\u003e Human datasets are \u003cstrong data-start=\"5026\" data-end=\"5048\"\u003eshort- to mid-term\u003c\/strong\u003e and modest in size; long-term \u003cstrong data-start=\"5079\" data-end=\"5107\"\u003eefficacy\/safety outcomes\u003c\/strong\u003e (CV events, fractures, prostate\/breast endpoints) remain \u003cstrong data-start=\"5165\" data-end=\"5179\"\u003eunresolved\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"5182\" data-end=\"5185\"\u003e\n\u003ch2 data-start=\"5187\" data-end=\"5220\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5222\" data-end=\"5756\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5222\" data-end=\"5260\"\u003e\n\u003ctr data-start=\"5222\" data-end=\"5260\"\u003e\n\u003cth data-start=\"5222\" data-end=\"5230\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5230\" data-end=\"5242\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5242\" data-end=\"5260\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5275\" data-end=\"5756\"\u003e\n\u003ctr data-start=\"5275\" data-end=\"5379\"\u003e\n\u003ctd data-start=\"5275\" data-end=\"5300\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5277\" data-end=\"5299\"\u003eSarcopenia\/frailty\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5300\" data-end=\"5340\" data-col-size=\"md\"\u003eOral anabolic with tissue selectivity\u003c\/td\u003e\n\u003ctd data-start=\"5340\" data-end=\"5379\" data-col-size=\"sm\"\u003ePhase 2 signals; larger RCTs needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5380\" data-end=\"5481\"\u003e\n\u003ctd data-start=\"5380\" data-end=\"5402\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5382\" data-end=\"5401\"\u003eCancer cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5402\" data-end=\"5451\" data-col-size=\"md\"\u003eAppetite-neutral anabolism vs ghrelin mimetics\u003c\/td\u003e\n\u003ctd data-start=\"5451\" data-end=\"5481\" data-col-size=\"sm\"\u003eMixed; subgroup strategies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5482\" data-end=\"5572\"\u003e\n\u003ctd data-start=\"5482\" data-end=\"5518\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5484\" data-end=\"5517\"\u003eAR-positive ER⁺ breast cancer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5518\" data-end=\"5553\" data-col-size=\"md\"\u003eAR agonism as antitumor strategy\u003c\/td\u003e\n\u003ctd data-start=\"5553\" data-end=\"5572\" data-col-size=\"sm\"\u003eOngoing studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5573\" data-end=\"5680\"\u003e\n\u003ctd data-start=\"5573\" data-end=\"5611\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5575\" data-end=\"5610\"\u003eOsteopenia\/osteoporosis adjunct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5611\" data-end=\"5653\" data-col-size=\"md\"\u003eBone-anabolic + anti-resorptive balance\u003c\/td\u003e\n\u003ctd data-start=\"5653\" data-end=\"5680\" data-col-size=\"sm\"\u003ePreclinical\/early human\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5681\" data-end=\"5756\"\u003e\n\u003ctd data-start=\"5681\" data-end=\"5702\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5683\" data-end=\"5701\"\u003eRehabilitation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5702\" data-end=\"5738\" data-col-size=\"md\"\u003eFaster strength\/function recovery\u003c\/td\u003e\n\u003ctd data-start=\"5738\" data-end=\"5756\" data-col-size=\"sm\"\u003ePilot concepts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5758\" data-end=\"5761\"\u003e\n\u003ch2 data-start=\"5763\" data-end=\"5792\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5794\" data-end=\"6611\"\u003e\n\u003cli data-start=\"5794\" data-end=\"5956\"\u003e\n\u003cp data-start=\"5796\" data-end=\"5956\"\u003e\u003cstrong data-start=\"5796\" data-end=\"5810\"\u003eEndocrine:\u003c\/strong\u003e \u003cstrong data-start=\"5811\" data-end=\"5865\"\u003eDose-dependent LH\/FSH and testosterone suppression\u003c\/strong\u003e (men); menses\/ovarian axis effects possible in women—generally \u003cstrong data-start=\"5929\" data-end=\"5943\"\u003ereversible\u003c\/strong\u003e post-stop.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5957\" data-end=\"6050\"\u003e\n\u003cp data-start=\"5959\" data-end=\"6050\"\u003e\u003cstrong data-start=\"5959\" data-end=\"5970\"\u003eLipids:\u003c\/strong\u003e \u003cstrong data-start=\"5971\" data-end=\"5991\"\u003eHDL-C reductions\u003c\/strong\u003e (often 10–20%); occasional \u003cstrong data-start=\"6019\" data-end=\"6031\"\u003e↑ LDL\/TG\u003c\/strong\u003e—monitor CV risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6051\" data-end=\"6202\"\u003e\n\u003cp data-start=\"6053\" data-end=\"6202\"\u003e\u003cstrong data-start=\"6053\" data-end=\"6065\"\u003eHepatic:\u003c\/strong\u003e Short trials show small median ALT\/AST changes; \u003cstrong data-start=\"6114\" data-end=\"6146\"\u003ecase reports of liver injury\u003c\/strong\u003e exist with unregulated SARM products—quality matters.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6203\" data-end=\"6274\"\u003e\n\u003cp data-start=\"6205\" data-end=\"6274\"\u003e\u003cstrong data-start=\"6205\" data-end=\"6212\"\u003eCV:\u003c\/strong\u003e No outcomes data; atherogenic lipid shifts warrant caution.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6275\" data-end=\"6360\"\u003e\n\u003cp data-start=\"6277\" data-end=\"6360\"\u003e\u003cstrong data-start=\"6277\" data-end=\"6294\"\u003eDermatologic:\u003c\/strong\u003e Mild \u003cstrong data-start=\"6300\" data-end=\"6317\"\u003eacne\/oiliness\u003c\/strong\u003e; \u003cstrong data-start=\"6319\" data-end=\"6336\"\u003ehair shedding\u003c\/strong\u003e in predisposed users.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6361\" data-end=\"6430\"\u003e\n\u003cp data-start=\"6363\" data-end=\"6430\"\u003e\u003cstrong data-start=\"6363\" data-end=\"6379\"\u003eHematologic:\u003c\/strong\u003e \u003cstrong data-start=\"6380\" data-end=\"6401\"\u003eMild ↑ hematocrit\u003c\/strong\u003e; monitor if baseline high.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6431\" data-end=\"6500\"\u003e\n\u003cp data-start=\"6433\" data-end=\"6500\"\u003e\u003cstrong data-start=\"6433\" data-end=\"6448\"\u003eNeuropsych:\u003c\/strong\u003e \u003cstrong data-start=\"6449\" data-end=\"6475\"\u003eIrritability, insomnia\u003c\/strong\u003e occasionally reported.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6501\" data-end=\"6611\"\u003e\n\u003cp data-start=\"6503\" data-end=\"6611\"\u003e\u003cstrong data-start=\"6503\" data-end=\"6525\"\u003eDrug interactions:\u003c\/strong\u003e Potential with agents affecting hepatic enzymes\/lipids; \u003cstrong data-start=\"6582\" data-end=\"6601\"\u003eavoid pregnancy\u003c\/strong\u003e exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6613\" data-end=\"6642\"\u003e\u003cstrong data-start=\"6613\" data-end=\"6642\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6644\" data-end=\"7177\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6644\" data-end=\"6715\"\u003e\n\u003ctr data-start=\"6644\" data-end=\"6715\"\u003e\n\u003cth data-start=\"6644\" data-end=\"6654\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6654\" data-end=\"6680\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6656\" data-end=\"6679\"\u003eEnobosarm (MK-2866)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6680\" data-end=\"6695\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6682\" data-end=\"6694\"\u003eLGD-4033\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6695\" data-end=\"6715\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6697\" data-end=\"6713\"\u003eTestosterone\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6734\" data-end=\"7177\"\u003e\n\u003ctr data-start=\"6734\" data-end=\"6793\"\u003e\n\u003ctd data-start=\"6734\" data-end=\"6747\" data-col-size=\"sm\"\u003eRoute \u0026amp; t½\u003c\/td\u003e\n\u003ctd data-start=\"6747\" data-end=\"6765\" data-col-size=\"sm\"\u003eOral; \u003cstrong data-start=\"6755\" data-end=\"6764\"\u003e~24 h\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"6765\" data-end=\"6781\" data-col-size=\"sm\"\u003eOral; 24–36 h\u003c\/td\u003e\n\u003ctd data-start=\"6781\" data-end=\"6793\" data-col-size=\"sm\"\u003eIM\/SC\/TD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6794\" data-end=\"6903\"\u003e\n\u003ctd data-start=\"6794\" data-end=\"6824\" data-col-size=\"sm\"\u003eLean-mass gain (short term)\u003c\/td\u003e\n\u003ctd data-start=\"6824\" data-end=\"6853\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6826\" data-end=\"6852\"\u003eYes (~1–1.5 kg\/12 wks)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6853\" data-end=\"6879\" data-col-size=\"sm\"\u003eYes (~0.6–1.5 kg\/3 wks)\u003c\/td\u003e\n\u003ctd data-start=\"6879\" data-end=\"6903\" data-col-size=\"sm\"\u003eYes (dose-dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6904\" data-end=\"6970\"\u003e\n\u003ctd data-start=\"6904\" data-end=\"6922\" data-col-size=\"sm\"\u003eHPG suppression\u003c\/td\u003e\n\u003ctd data-start=\"6922\" data-end=\"6937\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6924\" data-end=\"6936\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6937\" data-end=\"6948\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003ctd data-start=\"6948\" data-end=\"6970\" data-col-size=\"sm\"\u003eMarked (exogenous)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6971\" data-end=\"7021\"\u003e\n\u003ctd data-start=\"6971\" data-end=\"6987\" data-col-size=\"sm\"\u003eHDL reduction\u003c\/td\u003e\n\u003ctd data-start=\"6987\" data-end=\"7000\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6989\" data-end=\"6999\"\u003eCommon\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7000\" data-end=\"7009\" data-col-size=\"sm\"\u003eCommon\u003c\/td\u003e\n\u003ctd data-start=\"7009\" data-end=\"7021\" data-col-size=\"sm\"\u003eVariable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7022\" data-end=\"7081\"\u003e\n\u003ctd data-start=\"7022\" data-end=\"7037\" data-col-size=\"sm\"\u003eProstate\/PSA\u003c\/td\u003e\n\u003ctd data-start=\"7037\" data-end=\"7061\" data-col-size=\"sm\"\u003eLow change short-term\u003c\/td\u003e\n\u003ctd data-start=\"7061\" data-end=\"7067\" data-col-size=\"sm\"\u003eLow\u003c\/td\u003e\n\u003ctd data-start=\"7067\" data-end=\"7081\" data-col-size=\"sm\"\u003e↑ possible\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"7082\" data-end=\"7177\"\u003e\n\u003ctd data-start=\"7082\" data-end=\"7106\" data-col-size=\"sm\"\u003eHepatotoxicity signal\u003c\/td\u003e\n\u003ctd data-start=\"7106\" data-end=\"7139\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"7108\" data-end=\"7138\"\u003eCase reports (unregulated)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7139\" data-end=\"7154\" data-col-size=\"sm\"\u003eCase reports\u003c\/td\u003e\n\u003ctd data-start=\"7154\" data-end=\"7177\" data-col-size=\"sm\"\u003eLow (non-17-α oral)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7179\" data-end=\"7182\"\u003e\n\u003ch2 data-start=\"7184\" data-end=\"7210\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7212\" data-end=\"7464\"\u003e\n\u003cli data-start=\"7212\" data-end=\"7259\"\u003e\n\u003cp data-start=\"7214\" data-end=\"7259\"\u003e\u003cstrong data-start=\"7214\" data-end=\"7228\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-start=\"7229\" data-end=\"7237\"\u003eNone\u003c\/strong\u003e for any indication.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7260\" data-end=\"7383\"\u003e\n\u003cp data-start=\"7262\" data-end=\"7383\"\u003e\u003cstrong data-start=\"7262\" data-end=\"7278\"\u003eEnforcement:\u003c\/strong\u003e Regulatory agencies have issued \u003cstrong data-start=\"7311\" data-end=\"7323\"\u003ewarnings\u003c\/strong\u003e about SARM-containing “supplements” and \u003cstrong data-start=\"7364\" data-end=\"7380\"\u003eadulteration\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7384\" data-end=\"7464\"\u003e\n\u003cp data-start=\"7386\" data-end=\"7464\"\u003e\u003cstrong data-start=\"7386\" data-end=\"7396\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-start=\"7397\" data-end=\"7416\"\u003eWADA-prohibited\u003c\/strong\u003e (S1 Anabolic Agents); strict liability applies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7466\" data-end=\"7469\"\u003e\n\u003ch2 data-start=\"7471\" data-end=\"7494\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7496\" data-end=\"8084\"\u003e\n\u003cli data-start=\"7496\" data-end=\"7623\"\u003e\n\u003cp data-start=\"7498\" data-end=\"7623\"\u003e\u003cstrong data-start=\"7498\" data-end=\"7517\"\u003eDefinitive RCTs\u003c\/strong\u003e in \u003cstrong data-start=\"7521\" data-end=\"7550\"\u003esarcopenia\/rehabilitation\u003c\/strong\u003e, powered for \u003cstrong data-start=\"7564\" data-end=\"7596\"\u003efunction (SPPB, stair-power)\u003c\/strong\u003e and \u003cstrong data-start=\"7601\" data-end=\"7620\"\u003efalls\/fractures\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7624\" data-end=\"7760\"\u003e\n\u003cp data-start=\"7626\" data-end=\"7760\"\u003e\u003cstrong data-start=\"7626\" data-end=\"7647\"\u003eOncology programs\u003c\/strong\u003e in \u003cstrong data-start=\"7651\" data-end=\"7670\"\u003eAR-positive ER⁺\u003c\/strong\u003e breast cancer (rational combinations with \u003cstrong data-start=\"7713\" data-end=\"7734\"\u003eCDK4\/6 inhibitors\u003c\/strong\u003e and endocrine therapy).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7761\" data-end=\"7836\"\u003e\n\u003cp data-start=\"7763\" data-end=\"7836\"\u003e\u003cstrong data-start=\"7763\" data-end=\"7787\"\u003eBone-focused studies\u003c\/strong\u003e (DXA plus microarchitecture\/strength metrics).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7837\" data-end=\"7951\"\u003e\n\u003cp data-start=\"7839\" data-end=\"7951\"\u003e\u003cstrong data-start=\"7839\" data-end=\"7858\"\u003eSafety program:\u003c\/strong\u003e Long-term \u003cstrong data-start=\"7869\" data-end=\"7881\"\u003elipid\/CV\u003c\/strong\u003e, \u003cstrong data-start=\"7883\" data-end=\"7894\"\u003ehepatic\u003c\/strong\u003e, \u003cstrong data-start=\"7896\" data-end=\"7918\"\u003eendocrine recovery\u003c\/strong\u003e tracking with GMP drug supply.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7952\" data-end=\"8084\"\u003e\n\u003cp data-start=\"7954\" data-end=\"8084\"\u003e\u003cstrong data-start=\"7954\" data-end=\"7978\"\u003eMedicinal chemistry:\u003c\/strong\u003e Next-gen SARMs targeting \u003cstrong data-start=\"8004\" data-end=\"8024\"\u003elipid neutrality\u003c\/strong\u003e and \u003cstrong data-start=\"8029\" data-end=\"8056\"\u003ereduced HPG suppression\u003c\/strong\u003e while preserving anabolism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8086\" data-end=\"8089\"\u003e\n\u003ch3 data-start=\"8091\" data-end=\"8114\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8116\" data-end=\"8971\"\u003e\n\u003cli data-start=\"8116\" data-end=\"8277\"\u003e\n\u003cp data-start=\"8118\" data-end=\"8277\"\u003e\u003cstrong data-start=\"8118\" data-end=\"8212\"\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism; Journal of Cachexia, Sarcopenia and Muscle\u003c\/strong\u003e — Phase 2 human trials of enobosarm on lean mass and function.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8278\" data-end=\"8409\"\u003e\n\u003cp data-start=\"8280\" data-end=\"8409\"\u003e\u003cstrong data-start=\"8280\" data-end=\"8343\"\u003eFASEB Journal; American Journal of Physiology–Endocrinology\u003c\/strong\u003e — Anti-catabolic signaling and atrogene suppression with SARMs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8410\" data-end=\"8522\"\u003e\n\u003cp data-start=\"8412\" data-end=\"8522\"\u003e\u003cstrong data-start=\"8412\" data-end=\"8458\"\u003eJournal of Bone and Mineral Research; Bone\u003c\/strong\u003e — SARM effects on BMD and bone strength in osteopenia models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8523\" data-end=\"8659\"\u003e\n\u003cp data-start=\"8525\" data-end=\"8659\"\u003e\u003cstrong data-start=\"8525\" data-end=\"8580\"\u003eThe Oncologist; Cancer Research; Annals of Oncology\u003c\/strong\u003e — Enobosarm in cancer cachexia and AR-positive ER⁺ breast cancer strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8660\" data-end=\"8741\"\u003e\n\u003cp data-start=\"8662\" data-end=\"8741\"\u003e\u003cstrong data-start=\"8662\" data-end=\"8702\"\u003eClinical Pharmacology \u0026amp; Therapeutics\u003c\/strong\u003e — Oral PK\/PD of non-steroidal SARMs.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8742\" data-end=\"8856\"\u003e\n\u003cp data-start=\"8744\" data-end=\"8856\"\u003e\u003cstrong data-start=\"8744\" data-end=\"8796\"\u003eDrug Testing \u0026amp; Analysis; WADA Laboratory Reports\u003c\/strong\u003e — Detection of MK-2866 metabolites and anti-doping cases.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8857\" data-end=\"8971\"\u003e\n\u003cp data-start=\"8859\" data-end=\"8971\"\u003e\u003cstrong data-start=\"8859\" data-end=\"8911\"\u003eHepatology Communications; J Clin Transl Hepatol\u003c\/strong\u003e — Reports of liver injury with unregulated SARM products\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684868387154,"sku":"10","price":65.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/IMG-3973.png?v=1770834958","url":"https:\/\/sciencepeptideslab.com\/products\/ostarine-50x10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}